Secukinumab demonstrates high sustained efficacy and a favorable safety profile through five years of treatment in moderate-to-severe psoriasis

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2018
This article has no abstract
Epistemonikos ID: deb8e9bbaf5eb7f91b4a9875fdfb98c7b69715c4
First added on: Feb 15, 2022